>
Switch to:

Myovant Sciences Liabilities-to-Assets

: 1.91 (As of Mar. 2022)
View and export this data going back to 2016. Start your Free Trial

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Myovant Sciences's Total Liabilities for the quarter that ended in Mar. 2022 was $993.5 Mil. Myovant Sciences's Total Assets for the quarter that ended in Mar. 2022 was $520.0 Mil. Therefore, Myovant Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2022 was 1.91.


Myovant Sciences Liabilities-to-Assets Historical Data

The historical data trend for Myovant Sciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Liabilities-to-Assets
Premium Member Only Premium Member Only 0.68 0.98 2.02 1.49 1.91

Myovant Sciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Liabilities-to-Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.49 1.55 1.56 1.72 1.91

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Liabilities-to-Assets Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Liabilities-to-Assets falls into.



Myovant Sciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Myovant Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2022 is calculated as:

Liabilities-to-Assets (A: Mar. 2022 )=Total Liabilities/Total Assets
=993.488/520.011
=1.91

Myovant Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2022 is calculated as

Liabilities-to-Assets (Q: Mar. 2022 )=Total Liabilities/Total Assets
=993.488/520.011
=1.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences  (NYSE:MYOV) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Myovant Sciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo officer: Chief Medical Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie director C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen director C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Seely Lynn director, officer: Principal Executive Officer 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)